HER2 expression and its clinicopathological features in resectable gastric cancer (Q83629811)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

title

HER2 expression and its clinicopathological features in resectable gastric cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Yoshiki Kataoka

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Hiroshi Okabe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Akihiko Yoshizawa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Sachiko Minamiguchi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Kenichi Yoshimura

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Hironori Haga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

Yoshiharu Sakai

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

publication date

14 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

84-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22410801 AND SRC:MED&resulttype=core&format=json

Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients

25 January 2020

cites work

1 reference

12 December 2020

HER2 status in gastro‐oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)

1 reference

12 December 2020

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

1 reference

12 December 2020

Low frequency of HER2 amplification and overexpression in early onset gastric cancer.

1 reference

12 December 2020

c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems

1 reference

12 December 2020

Clinicopathological and prognostic significance of mucin phenotype in gastric cancer

1 reference

12 December 2020

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

1 reference

12 December 2020

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

12 December 2020

c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma.

1 reference

12 December 2020

The prognostic significance of p53, p27 kip1, p21 waf1, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients.

1 reference

12 December 2020

Lonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven

1 reference

12 December 2020

Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer

1 reference

12 December 2020

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

1 reference

12 December 2020

Predictors of Timing and Patterns of Recurrence after Curative Resection for Gastric Cancer

1 reference

12 December 2020

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

p53, the cellular gatekeeper for growth and division

1 reference

12 December 2020

Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray

1 reference

12 December 2020

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

12 December 2020

Comparative study on overexpression of HER2/neu and HER3 in gastric cancer

1 reference

12 December 2020

Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer

1 reference

12 December 2020

Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ Hybridization

1 reference

12 December 2020

p53 point mutations in primary human gastric carcinomas

1 reference

12 December 2020

Application of tyramide signal amplification system to immunohistochemistry: a potent method to localize antigens that are not detectable by ordinary method

1 reference

12 December 2020

Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction

1 reference

12 December 2020

A study of HER2 gene amplification and protein expression in gastric cancer

1 reference

12 December 2020

The prognostic significance of the mucin phenotype of gastric adenocarcinoma and its relationship with histologic classifications

1 reference

12 December 2020

Targeted HER2 treatment in advanced gastric cancer

1 reference

12 December 2020

HER-2 amplification is highly homogenous in gastric cancer

1 reference

12 December 2020

Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer

1 reference

12 December 2020

Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

1 reference

12 December 2020

Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma

1 reference

12 December 2020

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

HER2 testing in gastric cancer

1 reference

12 December 2020

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

1 reference

12 December 2020

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

12 December 2020